Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression

References

• Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012 Nov;1(4):491–6.
   PubMedGoogle Scholar
• Bech C, Sørensen JB. Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report. J Thorac Oncol. 2010 May;5(5):735–40. doi.org/10.1097/JTO.0b013e3181d86ea9.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636–44. doi.org/10.1200/JCO.2003.11.136.
   PubMed Web of Science ®Google Scholar
• Kanai O, Fujita K, Nakatani K, Mio T. Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma. Respirol Case Rep. 2016 Mar;4(1):28–31.
   PubMed Web of Science ®Google Scholar
• Giordano S, Zucchetti M, Decio A, Cesca M, Fuso Nerini I, Maiezza M, Ferrari M, Licandro SA, Frapolli R, Giavazzi R, et al. Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. Sci Rep. 2016 Dec 21;6:39284. doi.org/10.1038/srep39284.
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22:7468–85. doi.org/10.1038/sj.onc.1206948.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–37. doi.org/10.1016/j.taap.2004.10.012.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47:381–9. doi.org/10.1016/0092-8674(86)90595-7.
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–398. doi.org/10.1146/annurev.pharmtox.39.1.361.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNA. Genome Res. 2009;19:92–105. doi.org/10.1101/gr.082701.108.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58. doi.org/10.1038/nrc706.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. doi.org/10.1016/S0092-8674(04)00045-5.
   PubMed Web of Science ®Google Scholar
• Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24. doi.org/10.1101/gad.1399806.
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci U S A. 2007;104:9667–72. doi.org/10.1073/pnas.0703820104.
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–4. doi.org/10.1126/science.1149460.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54. doi.org/10.1016/0092-8674(93)90529-Y.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–14. doi.org/10.1038/nrg2634.
   PubMed Web of Science ®Google Scholar
• Hammond SM. RNAi, microRNAs and human diseases. Cancer Chemother Pharmacol. 2006;58:s63–8. doi.org/10.1007/s00280-006-0318-2.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27:5848–56. doi.org/10.1200/JCO.2009.24.0317.
   PubMed Web of Science ®Google Scholar
• Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16:430–41. doi.org/10.1158/1078-0432.CCR-09-1736.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8. doi.org/10.1038/nature03702.
   PubMed Web of Science ®Google Scholar
• Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007;26:293–300. doi.org/10.1089/dna.2006.0554.
   PubMed Web of Science ®Google Scholar
• Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, Cook J, Harris CC, Gius D, Mitchell JB. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One. 2009;4:e6377. doi.org/10.1371/journal.pone.0006377.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69. doi.org/10.1038/nrc1840.
   PubMed Web of Science ®Google Scholar
• Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle. 2008;7:2485–92. doi.org/10.4161/cc.7.16.6453.
   PubMed Web of Science ®Google Scholar
• Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, Gray J W, Pinkel D, Lluch A, Martinez-Climent JA. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 2007;67:818–26. doi.org/10.1158/0008-5472.CAN-06-3307.
   PubMed Web of Science ®Google Scholar
• Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther. 2007;6:1483–91. doi.org/10.1158/1535-7163.MCT-07-0009.
   PubMed Web of Science ®Google Scholar
• Mirski SE, Cole SP. Antigens associated with multidrug resistance in H69AR, a small cell lung cancer cell line. Cancer Res. 1989;49:5719–24.
   PubMed Web of Science ®Google Scholar
• Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Müller D, Olayioye MA. miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res. 2014 Sep 15;74(18):5256–65. doi.org/10.1158/0008-5472.CAN-13-3319.
   PubMed Web of Science ®Google Scholar
• Xu Y, Lin YP, Yang D, Zhang G, Zhou HF. Clinical Significance of miRNA149 in the Survival of Patients with Laryngeal Squamous Cell Carcinoma. Biomed Res Int. 2016;2016:8561251. doi.org/10.1155/2016/8561251.
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Fallah S, Ansari M. MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human glioblastoma multiforme. Biochem Cell Biol. 2016 Dec;94(6):569–76. doi.org/10.1139/bcb-2015-0064.
   PubMedGoogle Scholar
• Lin RJ, Lin YC, Yu AL. miRNA149# induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010 Aug;49(8):719–27.
   PubMed Web of Science ®Google Scholar
• Ke Y, Zhao W, Xiong J, Cao R. miRNA149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochem Res Int. 2013;2013:506731. doi.org/10.1155/2013/506731.
   PubMedGoogle Scholar
• Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res. 2011 Sep;37(7):427–34. doi.org/10.3109/01902148.2011.584263.
   PubMed Web of Science ®Google Scholar
• Ghosh RD, Ghuwalewala S, Das P, Mandloi S, Alam SK, Chakraborty J, Sarkar S, Chakrabarti S, Panda CK, Roychoudhury S. MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features. Sci Rep. 2016 Apr 5;6:23932. doi.org/10.1038/srep23932.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Xiang F, Wu R, Xu J, Ni Z, Jiang J, Kang X. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. J Ovarian Res. 2015 Jul 30;8:48. doi.org/10.1186/s13048-015-0178-7.
   PubMed Web of Science ®Google Scholar
• He DX, Gu XT, Li YR, Jiang L, Jin J, Ma X. Methylation-regulated miRNA149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J. 2014 Oct;281(20):4718–30. doi.org/10.1111/febs.13012.
   PubMed Web of Science ®Google Scholar
• Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495–535. doi.org/10.1146/annurev.pharmtox.48.080907.180426.
   PubMed Web of Science ®Google Scholar
• Pires MM, Emmert D, Hrycyna CA, Chmielewski J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol. 2009 Jan;75(1):92–100. doi.org/10.1124/mol.108.050492.
   PubMed Web of Science ®Google Scholar
• Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R, Dash S. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 2011 Feb;178(2):838–52. doi.org/10.1016/j.ajpath.2010.10.029.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang H, Zhao L, Fan S, Yang Z, Gao F, Chen L, Xiao GG, Molnár J, Wang Q. Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res. 2010 Sep;30(9):3593–8.
   PubMed Web of Science ®Google Scholar
• Stordal B, Pavlakis N, Davey R. Treating cisplatin-resistant cancer: A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. In: Bonetti A, Leone R, Muggia FM, Howell SB, editors. Platinum and other heavy metal compounds in cancer chemotherapy. Cancer drug discovery and development. Totowa (NJ): Humana Press; 2009.
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8. doi.org/10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar